Bruce Strober1, Caitriona Ryan2, Peter van de Kerkhof3, Joelle van der Walt4, Alexa B Kimball5, Jonathan Barker6, Andrew Blauvelt7. 1. Yale University School of Medicine, New Haven, Connecticut; Central Connecticut Dermatology, Cromwell, Connecticut. Electronic address: strober@centralctderm.com. 2. Blackrock Clinic Dublin and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland. 3. International Psoriasis Council, St Louis, Missouri. 4. International Psoriasis Council, St Louis, Missouri. Electronic address: info@psoriasiscouncil.com. 5. Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts. 6. St John's Institute of Dermatology, King's College London, London, United Kingdom. 7. Oregon Medical Research Center, Portland, Oregon.
Abstract
BACKGROUND: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis. OBJECTIVE: To develop a consensus statement on the classification of psoriasis severity. METHODS: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity. RESULTS: After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy. LIMITATIONS: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients. CONCLUSION: The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
BACKGROUND:Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis. OBJECTIVE: To develop a consensus statement on the classification of psoriasis severity. METHODS: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity. RESULTS: After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasispatients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy. LIMITATIONS: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients. CONCLUSION: The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
Authors: Kristian Reich; Diamant Thaçi; Georg Stingl; Jens Strodl Andersen; Line Conradsen Hiort; Michala Oron Lexner; David Winkler; Carle Paul Journal: Acta Derm Venereol Date: 2022-03-28 Impact factor: 3.875
Authors: Julie J Hong; Megan L Mosca; Edward K Hadeler; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao Journal: Dermatol Ther (Heidelb) Date: 2021-04-29
Authors: Laura Salgado-Boquete; José Manuel Carrascosa; Mar Llamas-Velasco; Ricardo Ruiz-Villaverde; Pablo de la Cueva; Isabel Belinchón Journal: Life (Basel) Date: 2021-06-29
Authors: Cæcilie Bachdal Johansen; Alexander Egeberg; Espen Jimenez Solem; Ida Vittrup; Lone Skov; Simon Francis Thomsen Journal: Int J Womens Dermatol Date: 2020-11-27